FDA批准FreeStyle Libre 2 App用于糖尿病管理

2021-08-17 MedSci原创 MedSci原创

糖尿病管理一直是慢病管理领域的热点。

糖尿病管理一直是慢病管理领域的热点。 美国食品药品监督管理局(FDA)已批准Freestyle Libre 2 iOS应用于糖尿病患者的动态血糖监测,为Freestyle Libre 2集成动态血糖监测系统提供全面的数字化服务。本次批准允许4岁及以上的糖尿病患者在不使用专门的读数器的情况下在其兼容的智能手机上获得血糖读数。 应用程序 该APP旨在为使用Freestyle Libre 2葡萄糖传感器的患者提供个性化、最新血糖数据,用于糖尿病管理。 使用Freestyle Libre 2应用程序扫描传感器后,患者将收到其当前血糖读数和趋势,以帮助确定食物、运动和生活方式因素对糖尿病管理的影响。Freestyle Libre 2的佩戴时间为14天,可在药店购买。 其他功能包括可选的实时血糖报警(用于提醒用户血糖水平)、8小时血糖历史记录(带有趋势)以及集成数字健康工具(允许用户与医疗保健专业人员共享其血糖读数)。 反应 雅培糖尿病护理高级副总裁Jared Watkin在一份声明中表示,这款应用将使得人们管理自己的糖尿病变得简单,赋予用户可随时随地访问信息的能力。 Watkin说:“如何与糖尿

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-09-16 lsj640
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-04-02 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-18 小火龙111

    nice

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-18 小火龙111

    nice

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-18 小火龙111

    nice

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2051677, encodeId=d4dc20516e71a, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Mar 23 05:07:18 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755792, encodeId=b2a11e557924d, content=<a href='/topic/show?id=6460e65996' target=_blank style='color:#2F92EE;'>#freestyle#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7659, encryptionId=6460e65996, topicName=freestyle)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d23d37034528, createdName=lsj640, createdTime=Thu Sep 16 10:07:18 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839935, encodeId=12741839935b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Apr 02 23:07:18 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931719, encodeId=220a1931e19b6, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Fri Apr 15 01:07:18 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009122, encodeId=0c7a1009122c8, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:43 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009121, encodeId=72fc1009121a4, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:41 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009120, encodeId=35b7100912049, content=nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Wed Aug 18 15:19:38 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043740, encodeId=201f1043e409a, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Aug 17 13:07:18 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Nutrition:补充益生菌和益生元对成年糖尿病患者肠道微生物群的影响

肠道微生物群中16S rRNA基因分析表明,与健康人群相比,肥胖和糖尿病患者的厚壁菌门-拟杆菌门及比例更高。因此,看来通过益生菌/预生菌/合成菌对肠道微生物生态的调控可能有助于代谢性疾病的进展和预防。

Cardiovasc Diabetol:心脏脂肪体积和IL-6水平可预测糖尿病患者因新冠肺炎入院后的短期病情恶化和死亡风险

对因新冠肺炎入院的糖尿病患者进行心脏脂肪组织指数和IL-6测定,可以帮助医生更好地识别具有高短期内病情迅速恶化和早期死亡风险的患者

Diabetes Obes Metab:与单用德谷胰岛素相比,IDegLira可以显著降低HbA1c、减轻体重及降低低血糖风险

德谷胰岛素/利拉鲁肽复方制剂(IDegLira)作为一种新型复方药物,与德谷胰岛素单药制剂相比,可以显著改善了血糖水平,降低体重以及减少低血糖发生率

Metabolism:伴有糖尿病/应激性高血糖的COVID-19肺炎患者血栓栓塞风险

伴有糖尿病/应激性高血糖症的COVID-19肺炎患者血栓栓塞风险较高,并且与较差的临床结局相关。如果感染了SARS-Cov-2,同时伴有糖尿病/应激性高血糖症的患者可以考虑进行更强化的预防性抗凝治疗。

Nat Med:全自动闭环血糖控制与标准胰岛素治疗2型糖尿病患者的比较:一项开放标签、随机交叉试验 

最近,研究人员评估了在需要透析的2型糖尿病成人患者中,全闭环胰岛素治疗与标准胰岛素治疗相比的安全性和有效性。

Lancet子刊:“明星药”利拉鲁肽对超重和肥胖成人内脏脂肪的影响

对于已发生糖尿病及冠心病的胖人而言,减轻体重,改善胰岛素敏感性,是治疗的基础。